Cosmo Feilding Mellen

Oxford, England, United Kingdom

Atai Makes $50 Million Investment Into Beckley Psytech

Psychedelic biotech company atai Life Sciences (NASDAQ: ATAI) announced a strategic investment in Beckley Psytech Limited, a private clinical-stage biotechnology company dedicated to transforming short-duration...

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage...

Palo Santo Closes $50 Million Psychedelic Investment Fund

Palo Santo Closes $50 Million Psychedelic Therapeutics Investment Fund With an Active Portfolio and Additional Capital to Deploy, Palo Santo Fund is Positioned to Accelerate...

Beckley Psytech

Director & CEO

Last updated: Jul 08, 2020

Request Deletion